Pyridostigmine
Mestinon, Pyridostigmine, Regonol (pyridostigmine) is a small molecule pharmaceutical. Pyridostigmine was first approved as Mestinon on 1982-01-01. It is used to treat drug-induced abnormalities and myasthenia gravis in the USA. It is known to target cholinesterase and acetylcholinesterase.
Download report
Favorite
Events Timeline
Commercial
Clinical
Drug
Target
Variants
Financial
Trends
Safety
Events Timeline
5D
1M
3M
6M
YTD
1Y
2Y
5Y
Max
Events
FDA approval date
EMA approval date
Patent expiration date
Study first post date
Last update post date
Start date
Primary completion date
Completion date
Results first post date
Mock data
Subscribe for the real data
Subscribe for the real data
Commercial
Therapeutic Areas
Trade Name
FDA
EMA
Mestinon, Pyridostigmine, Regonol (discontinued: Pyridostigmine)
Drug Products
FDA
EMA
New Drug Application (NDA)
New Drug Application (NDA)
Abbreviated New Drug Application (ANDA)
Abbreviated New Drug Application (ANDA)
Pyridostigmine bromide
Tradename | Company | Number | Date | Products |
|---|---|---|---|---|
| MESTINON | Bausch Health Companies | N-009830 RX | 1982-01-01 | 1 products, RLD, RS |
| MESTINON | Bausch Health Companies | N-015193 RX | 1982-01-01 | 1 products, RLD, RS |
| MESTINON | Bausch Health Companies | N-011665 RX | 1982-01-01 | 1 products, RLD, RS |
| MESTINON | Bausch Health Companies | N-009829 RX | 1982-01-01 | 1 products, RLD, RS |
| REGONOL | Sandoz | N-017398 RX | 1982-01-01 | 1 products |
Show 2 discontinued
Labels
FDA
EMA
Brand Name | Status | Last Update |
|---|---|---|
| mestinon | New Drug Application | 2020-12-02 |
| mestinon mestinon timespan | 2006-10-02 | |
| pryidostigmine bromide | ANDA | 2025-01-09 |
| pyridostigmine | ANDA | 2019-03-11 |
| pyridostigmine bromide | ANDA | 2025-10-03 |
| regonol | New Drug Application | 2022-10-13 |
Indications
FDA
EMA
Indication | Ontology | MeSH | ICD-10 |
|---|---|---|---|
| myasthenia gravis | EFO_0004991 | D009157 | G70.0 |
| drug-induced abnormalities | — | D000014 | — |
Agency Specific
FDA
EMA
No data
Patent Expiration
No data
HCPCS
No data
Clinical
Clinical Trials
53 clinical trials
View more details
Mock data
Subscribe for the real data
Subscribe for the real data
Indications Phases 4
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Myasthenia gravis | D009157 | EFO_0004991 | G70.0 | 1 | 1 | 3 | 2 | 5 | 12 |
| Muscle weakness | D018908 | — | — | — | — | 2 | 2 | 5 | 9 |
| Hypotension | D007022 | EFO_0005251 | I95 | 1 | 3 | — | 1 | — | 5 |
| Orthostatic hypotension | D007024 | — | I95.1 | 1 | 3 | — | 1 | — | 5 |
| Postural orthostatic tachycardia syndrome | D054972 | — | G90.A | 2 | 2 | — | 1 | — | 5 |
| Tachycardia | D013610 | — | R00.0 | 1 | 2 | — | 1 | — | 4 |
| Syndrome | D013577 | — | — | — | 2 | — | 1 | — | 3 |
| Muscle relaxation | D009126 | — | — | — | — | — | 1 | 1 | 2 |
| Prostatic hyperplasia | D011470 | EFO_0000284 | N40 | — | 1 | — | 1 | — | 2 |
| Hyperplasia | D006965 | EFO_0000536 | — | — | 1 | — | 1 | — | 2 |
Show 10 more
Indications Phases 3
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Covid-19 | D000086382 | — | U07.1 | — | 1 | 1 | — | — | 1 |
| Sars-cov-2 | D000086402 | — | — | — | 1 | 1 | — | — | 1 |
| Leukemia | D007938 | — | C95 | — | — | 1 | — | — | 1 |
| Ileus | D045823 | — | K56.7 | — | 1 | 1 | — | — | 1 |
Indications Phases 2
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Diabetes mellitus | D003920 | EFO_0000400 | E08-E13 | 2 | 1 | — | — | 1 | 3 |
| Hiv infections | D015658 | EFO_0000764 | B20 | 1 | 2 | — | — | — | 3 |
| Muscular atrophy | D009133 | — | — | — | 2 | — | — | — | 2 |
| Spinal muscular atrophy | D009134 | EFO_0003823 | G12.1 | — | 2 | — | — | — | 2 |
| Atrophy | D001284 | — | — | — | 2 | — | — | — | 2 |
| Spinal muscular atrophies of childhood | D014897 | Orphanet_83419 | G12.1 | — | 2 | — | — | — | 2 |
| Orthostatic intolerance | D054971 | — | — | 1 | 1 | — | — | — | 2 |
| Chronic fatigue syndrome | D015673 | EFO_0004540 | G93.31 | — | 2 | — | — | — | 2 |
| Fibromyalgia | D005356 | EFO_0005687 | M79.1 | — | 2 | — | — | — | 2 |
| Parkinson disease | D010300 | EFO_0002508 | G20 | — | 2 | — | — | — | 2 |
Show 31 more
Indications Phases 1
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Pure autonomic failure | D054970 | — | — | 1 | — | — | — | — | 1 |
| Glycogen storage disease type ii | D006009 | Orphanet_365 | E74.02 | 1 | — | — | — | — | 1 |
| Acquired immunodeficiency syndrome | D000163 | EFO_0000765 | B20 | 1 | — | — | — | — | 1 |
| Inflammation | D007249 | MP_0001845 | — | 1 | — | — | — | — | 1 |
| Job syndrome | D007589 | EFO_0003775 | D82.4 | 1 | — | — | — | — | 1 |
| Pharmacokinetics | D010599 | — | — | 1 | — | — | — | — | 1 |
Indications Without Phase
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Neuromuscular blockade | D019148 | — | — | — | — | — | — | 2 | 2 |
| Colorectal neoplasms | D015179 | — | — | — | — | — | — | 1 | 1 |
| Fatal outcome | D017809 | — | — | — | — | — | — | 1 | 1 |
| Diabetic neuropathies | D003929 | EFO_1000783 | — | — | — | — | — | 1 | 1 |
| Gastrointestinal motility | D005769 | — | — | — | — | — | — | 1 | 1 |
| Muscle hypotonia | D009123 | — | — | — | — | — | — | 1 | 1 |
| Diabetes complications | D048909 | — | — | — | — | — | — | 1 | 1 |
| Intraoperative complications | D007431 | — | — | — | — | — | — | 1 | 1 |
| Trismus | D014313 | — | — | — | — | — | — | 1 | 1 |
| General anesthesia | D000768 | — | — | — | — | — | — | 1 | 1 |
Show 2 more
Epidemiology
Epidemiological information for investigational and approved indications
View more details
Drug
General
| Drug common name | Pyridostigmine |
| INN | pyridostigmine bromide |
| Description | Pyridostigmine is a medication used to treat myasthenia gravis. It is also used together with atropine to end the effects of neuromuscular blocking medication of the non-depolarizing type. It is typically given by mouth but can also be used by injection. The effects generally begin within 45 minutes and last up to 6 hours.
|
| Classification | Small molecule |
| Drug class | cholinesterase inhibitors (physostigmine type) |
| Image (chem structure or protein) |  |
| Structure (InChI/SMILES or Protein Sequence) | CN(C)C(=O)Oc1ccc[n+](C)c1 |
Identifiers
| PDB | — |
| CAS-ID | 155-97-5 |
| RxCUI | — |
| ChEMBL ID | CHEMBL1115 |
| ChEBI ID | 8665 |
| PubChem CID | 4991 |
| DrugBank | DB00545 |
| UNII ID | KVI301NA53 (ChemIDplus, GSRS) |
Target
Agency Approved
No data
Alternate
BCHE
BCHE
ACHE
ACHE
Organism
Homo sapiens
Gene name
BCHE
Gene synonyms
CHE1
NCBI Gene ID
Protein name
cholinesterase
Protein synonyms
Acylcholine acylhydrolase, Butyrylcholine esterase, Choline esterase II, cholinesterase (serum) 2, cholinesterase 1, Pseudocholinesterase
Uniprot ID
Mouse ortholog
Bche (12038)
cholinesterase (Q543J3)
Variants
No data
Financial
Revenue by drug
$
€
£
â‚£
No data
Estimated US medical usage
Pyridostigmine
Total medical expenditures per year (USD, in millions)
Mock data
Subscribe for the real data
Subscribe for the real data
Number of persons purchased
Mock data
Subscribe for the real data
Subscribe for the real data
Number of purchases
Mock data
Subscribe for the real data
Subscribe for the real data
Refill frequency
Mock data
Subscribe for the real data
Subscribe for the real data
Price per prescription (USD)
Mock data
Subscribe for the real data
Subscribe for the real data
Tabular view
Trends
PubMed Central
Top Terms for Disease or Syndrome:
Mock data
Subscribe for the real data
Subscribe for the real data
Additional graphs summarizing 5,824 documents
View more details
Safety
Black-box Warning
No Black-box warning
Adverse Events
Top Adverse Reactions
Mock data
Subscribe for the real data
Subscribe for the real data
2,265 adverse events reported
View more details
© 2020-2025 Collaborative Drug Discovery Inc. (CDD) | Terms of Use